CD274 and neoplasm: These first results, suggesting a greater benefit during early use, and when the tumor expresses PD-L1 by immunohistochemistry, were confirmed in the phase III Keynote 119 study, in which pembrolizumab monotherapy was used in second or third line of metastatic TNBC treatment, without better ORR as compared to single-agent chemotherapy.